Roche hit for $6.3bn due to biosimilar competition

Retrieved on: 2021-02-08 10:41:15

Tags for this article:

Click the tags to see associated articles and topics

Roche hit for $6.3bn due to biosimilar competition. View article details on hiswai:

Excerpt

Roche group's CEO, Severin Schwan, commented in an investor call after the results were revealed that “the impact of biosimilars was significant, ...

Article found on: bioprocessintl.com